Article
Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies.
Science signaling - 28 Mar 2023
Germon Zacary P, Sillar Jonathan R, Mannan Abdul, Duchatel Ryan J, Staudt Dilana, Murray Heather C, Findlay Izac J, Jackson Evangeline R, McEwen Holly P, Douglas Alicia M, McLachlan Tabitha, Schjenken John E, Skerrett-Byrne David A, Huang Honggang, Melo-Braga Marcella N, Plank Maximilian W, Alvaro Frank, Chamberlain Janis, De Iuliis Geoff, Aitken R John, Nixon Brett, Wei Andrew H, Enjeti Anoop K, Huang Yizhou, Lock Richard B, Larsen Martin R, Lee Heather, Vaghjiani Vijesh, Cain Jason E, de Bock Charles E, Verrills Nicole M, Dun Matthew D
Abstract excerpt
Mutations in the type III receptor tyrosine kinase FLT3 are frequent in patients with acute myeloid leukemia (AML) and are associated with a poor prognosis. AML is characterized by the overproduction of reactive oxygen species (ROS), which can induce cysteine oxidation in redox-sensitive signaling proteins. Here, we sought to characterize the specific pathways affected by ROS in AML by assessing oncogenic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.